Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study - Top-Institutions - MDSpire

Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study

  • By

  • Ozlem Candan

  • Narmin Naghizada

  • Tekin Tuncel

  • Beyza Melek Palaz

  • Mustafa Alperen Tunc

  • Derya Demirtas

  • Ahmet Mert Yanik

  • Arda Bayar

  • Secil Salim

  • Fatma Temiz

  • Ceren Uzunoglu Guren

  • Fatma Arıkan

  • Meral Ulukoylu Menguc

  • Asu Fergun Yilmaz

  • Isik Atagunduz

  • Zekaver Odabası

  • Tayfur Toptas

  • Ayse Tulin Tuglular

  • May 14, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Hematology

  • #3

    Medical College of Wisconsin
    Medical College of Wisconsin

    Milwaukee, WI

    Key Differentiators

    • Hematology

  • #4

    Washington University School of Medicine
    Washington University School of Medicine

    St. Louis, MO

    Key Differentiators

    • Hematology

  • #5

    McMaster University
    McMaster University

    Hamilton, ON

    Key Differentiators

    • Hematology

Original Source(s)

Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study

  • by Ozlem Candan, Narmin Naghizada, Tekin Tuncel, Beyza Melek Palaz, Mustafa Alperen Tunc, Derya Demirtas, Ahmet Mert Yanik, Arda Bayar, Secil Salim, Fatma Temiz, Ceren Uzunoglu Guren, Fatma Arıkan, Meral Ulukoylu Menguc, Asu Fergun Yilmaz, Isik Atagunduz, Zekaver Odabası, Tayfur Toptas, Ayse Tulin Tuglular

  • May 14, 2026

Related Content

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min
Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.